Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02352675 · ClinicalTrials.gov registry record

Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis

A clinical trial of Congenital Heart Disease and Rotational Thromboelastometry, sponsored by Boston Children's Hospital.

Completed
Registry status
40
Enrollment target
1
Study location

NCT02352675: Completed study of Congenital Heart Disease and Rotational Thromboelastometry, sponsored by Boston Children's Hospital.

NCT02352675 is a study of Congenital Heart Disease and Rotational Thromboelastometry that has completed, run by Boston Children's Hospital. The registered enrollment target is 40 participants, below the 473-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02352675, a study of Congenital Heart Disease and Rotational Thromboelastometry, has completed, sponsored by Boston Children's Hospital.

COMPLETED
Registry status
40 participants
Enrollment target
1
Study location

Study Summary

Lysine analogs, like tranexamic acid (TXA) or epsilon aminocaproic acid (EACA), are antifibrinolytic agents routinely administered in children undergoing different surgeries associated with a high bleeding risk (e.g. cardiac, craniofacial, and orthopedic surgeries). Although there is a growing literature regarding the pharmacokinetic characteristics of these drugs in children, the plasmatic concentration required to completely inhibit fibrinolysis remains to be determined. In this in vitro study, the investigators will use an experimental model of fibrinolysis designed for rotational thromboelastometry (ROTEM®) to determine the minimal concentration inhibiting fibrinolysis for both TXA and EACA. In addition, this study will be used to create and validate a new experimental assay to measure fibrinolysis and the effect of antifibrinolytic agents.

Interventions

  • OTHER Intraoperative Blood Sample

Study Locations (1)

Massachusetts

  • Boston Children's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2015-04
Est. Completion 2016-03
Boston Children's Hospital

462 total trials

What the finished NCT02352675 record still lists

NCT02352675 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 473-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (92% lower).

The record links to 3 conditions, with Congenital Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which Intraoperative Blood Sample is the first listed.

NCT02352675 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02352675 about?

NCT02352675 is a clinical study titled "Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis". Lysine analogs, like tranexamic acid (TXA) or epsilon aminocaproic acid (EACA), are antifibrinolytic agents routinely administered in children undergoing different surgeries associated with a high bleeding risk (e.g. cardiac, craniofacial, and orthopedic surgeries). Although there is a growing liter...

What is the current status of trial NCT02352675?

This trial is currently completed. The enrollment target is 40 participants. The study started on 2015-04. Estimated completion is 2016-03.

What conditions does trial NCT02352675 study?

This clinical trial studies the following conditions: Congenital Heart Disease, Rotational Thromboelastometry, Fibrinolysis.

What interventions are being tested in trial NCT02352675?

The interventions under investigation include: Intraoperative Blood Sample (OTHER).

Who is sponsoring clinical trial NCT02352675?

This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02352675 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Congenital Heart Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02352675's enrollment target sits among peer trials

40 49th of 63 higher than 13 of 63 other Congenital Heart Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Congenital Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02352675, the US trial registry maintained by the National Library of Medicine. NCT02352675 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.